Navigation Links
Reportlinker Adds Global Anti-CD20 Monoclonal Antibodies Industry
Date:10/4/2010

NEW YORK, Oct. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anti-CD20 Monoclonal Antibodies Industry

http://www.reportlinker.com/p0305155/Global-Anti-CD20-Monoclonal-Antibodies-Industry.html

This report analyzes the Global market for Anti-CD20 Monoclonal Antibodies in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 38 companies including many key and niche players such as Bayer Schering Pharma AG, Biocon, Biogen Idec, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genmab A/S, GlaxoSmithKline Plc, GTC Biotherapeutics, Inc., Immunomedics, Inc., InNexus Biotechnology, Inc., LFB Group, Nycomed, Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Trubion Pharmaceuticals, Inc., and UCB Pharmaceutical. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTI-CD20 MONOCLONAL ANTIBODIES MCP-6217

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1

Current and Future Analysis II-1

Monoclonal Antibody Market Garners Riches II-1

Rituxan/MabThera to Remain the Market Leader II-2

Rituxan's Success Spurs Development of New Anti-CD20 Antibodies II-2

Clinical Trial Failures Trouble Drug Makers, Retracts Market

Growth II-3

Safety Issues Marr Penetration of Radiolabelled CD20 Antibodies II-3

Oncologists Resort to Zevalin and Bexxar As a Last Resort II-3

Novel Action Mechanisms Bode Potential for New CD20 mAbs II-4

Future of mAbs – Smaller and Inexpensive to Produce II-4

Structurally Modified Full-Size mAbs – Next Type of mAbs to

Hit the Market II-5

MAb Fragments II-5

Major Companies in the Chase for New-Generation Technologies II-5

Next Generation CD20 mABs II-6

Comparison of Marketed and Pipeline CD20 Antibodies Based on

Action Mechanism II-6

Second Generation CD20 Antibodies II-6

Ofatumumab II-6

Veltuzumab II-7

Ocrelizumab II-7

Third Generation CD20 Antibodies II-7

AME133v II-7

TRU-015 II-7

GA101/Obinutuzumab II-7

Incidence and Prevalence of Major Targeted Indications of CD20

mAbs II-8

Rheumatoid Arthritis – A Chronic, Debilitating Disease II-8

Incidence and Prevalence Higher in Urban and Developed Regions II-8

Lymphoma Incidence and Mortality Rates On the Rise II-9

Incidence of Hodgkin's Lymphoma - High in West Asia II-9

Table 1: Age-Standardized Incidence Rates for Hodgkin's

Lymphoma in Select Countries Worldwide (2002) (includes

corresponding Graph/Chart) II-9

Table 2: Age-Standardized Mortality Rates for Hodgkin's

Lymphoma in Select Countries Worldwide (2002) (includes

corresponding Graph/Chart) II-10

2. MARKET DYNAMICS II-11

PML Risks Clipping Label Expansions of Rituxan II-11

Rituxan and Ocrelizumab Show Promise in RRMS Treatment II-11

Ocrelizumab's Ouster in RA Puts Development Partners in a

Quandary II-12

Zevalin and Bexxar Sales Remain in Obscurity II-13

The Road Ahead for Zevalin II-13

3. FOCUS ON SELECT ANTI-CD20 MABS AVAILABLE WORLDWIDE II-14

APPROVED ANTI-CD20 ANTIBODIES IN A NUTSHELL II-14

Select Anti-CD20 Antibodies' Pipeline in a Nutshell II-14

Drug Details II-16

Rituxan/MabThera (Biogen, Roche and Genentech) II-16

Approved and Potential Indications for Rituxan II-17

Zevalin (Spectrum™ Pharmaceuticals) II-17

Bexxar (GlaxoSmithKline) II-18

Ofatumumab (Genmab and GlaxoSmithKline) II-18

Clinical Development of HuMax-CD20 by Indication and Stage

of Development II-19

Ocrelizumab (Biogen/Genentech) II-19

Summary of Ocrelizumab Development Status II-20

GA-101 (Roche/GlycArt) II-20

TRU-015 (Trubion) II-21

AME-133v (Eli Lilly) II-21

Veltuzumab (Immunomedics/Nycomed) II-22

Clinical Trials of Veltuzumab II-22

BVX-20 (Biocon) II-23

LFB-R603 (LFB Biotechnlogies) II-23

DXL625 (InNexus) II-23

4. PRODUCT OVERVIEW II-24

CD20 Antibody II-24

Immune System: Natural Defenders II-24

Human Antibodies II-24

Types of Monoclonal Antibodies II-24

Table 3: Worldwide mAb Market By Product Type (2008):

Percentage Share Breakdown For Chimeric, Humanized, Human And

Murine (includes corresponding Graph/Chart) II-24

Chimeric Antibodies: Show Lesser Antigenicity II-25

Murine Monoclonal Antibodies II-25

Humanized Antibodies/ CDR Grafted Antibodies (Human Antibodies) II-25

Fully Human Antibodies II-26

Bispecific Antibodies II-26

5. A PEEK INTO MONOCLOBAL ANTIBODY MARKET II-27

EVOLUTION OF MONOCLONAL ANTIBODIES – A HISTORICAL JOURNEY II-27

Market Perspective of mAbs II-28

Regional Perspective II-28

Significant Growth Awaits mAbs II-28

Shift Towards Humanized and Fully Human Antibodies II-29

Ageing Baby Boomers Spur MAbs Growth II-30

Non-Existent Generic Competition Favors MAb Market II-30

Rising Number of MAbs Under Clinical Trials II-30

High Costs Impede MAbs Penetration II-30

Opportunities in Technology Development II-31

Advancements & Challenges in Antibody Production Processes II-31

Increasing Demand for Protein A in MAb Manufacturing II-32

6. RECENT DRUG APPROVALS AND REGULATORY STATUS II-33

RITUXAN RECEIVES FDA APPROVAL FOR THE TREATMENT OF Chronic

Lymphocytic Leukemia II-33

GSK Receives Positive Opinion for Arzerra™ from EMEA II-33

LFB Obtains Orphan Drug Status for LFB-R603 in Europe II-34

FDA Grants Accelerated Approval for GSK and Genmab's

Ofatumumab for Chronic Lymphocytic Leukemia II-34

InNexus's DXL625 Receives Positive Opinion from FDA II-34

Spectrum Pharma Obtains FDA Approval for Zevalin's Expanded

Label in NHL Treatment II-35

Bayer Schering Obtains EU Approval for Zevalin in First-Line

Treatment II-35

7. RECENT INDUSTRY ACTIVITY II-36

Pfizer Discontinues Development of TRU-015; Continues to

Develop SBI-087 II-36

Roche and Biogen Discontinue Ocrelizumab Development in

Rheumatoid Arthritis II-36

Roche and Biogen File Patent Suit Against GSK II-37

Ocrelizumab Meets Primary End-Point In Phase III Trial for RA II-37

Rituxan Plus FC Chemotherapy Shows Improved Survival in

Treatment-Naïve CLL Patients II-37

FDA Declines Early Use of Rituxan in RA II-38

LG Life Sciences Announces New Anti-CD20 Antibody Program II-38

Provenance Acquires Global Rights to New Anti-CD20 Antibody

from Merck II-38

Roche Takes Over Genentech II-39

Pfizer Acquires Wyeth II-39

Spectrum Pharma Acquires Lymphoma Drug Zevalin II-39

Biogen Partners with Genentech and Roche for Development of

GA-101 II-39

Roche, GlycArt and Genentech Team Up for Development of GA-101 II-40

InNexus Biotechnology Discovers New Anti-CD20 Antibody, DXLr120 II-40

MRC Completes Humanization of Biolex's Anti-CD20 Antibody,

BLX-301 II-40

Immunomedics Inks Licensing and Collaboration Deal with Nycomed II-40

Rituxan Fails To Meet Primary End-Point in Phase II/III Trial

for SLE II-41

Rituxan Fails To Meet Primary End-Point in Phase II/III Trial

for PPMS II-41

Rituxan Meets Primary End-point in Phase III Trial for DMARD

Inadequate Responders in RA II-41

Cell Therapeutics Acquires Zevalin from Biogen Idec II-42

InNexus Develops Dxl625 Anti-Cd20 Monoclonal Antibody II-42

GTC and LFB Commence Development of Novel Anti-CD20 Antibody II-42

Favrille Purchases Anti-CD20 mAbs from Diversa II-43

Genmab and GSK Ink Global Collaboration Agreement for HuMax-CD20 II-43

8. FOCUS ON SELECT MARKET PARTICIPANTS II-44

Bayer Schering Pharma AG (Germany) II-44

Biocon (India) II-44

Biogen Idec, Inc. (US) II-45

Eli Lilly and Company (US) II-46

F. Hoffmann-La Roche Ltd. (Switzerland) II-46

Genentech, Inc. (US) II-47

Genmab A/S (Denmark) II-47

GlaxoSmithKline Plc. (UK) II-48

GTC Biotherapeutics, Inc. (US) II-49

Immunomedics, Inc. (US) II-49

InNexus Biotechnology, Inc. (Canada) II-50

LFB Group (France) II-50

Nycomed (Switzerland) II-51

Pfizer, Inc. (US) II-51

Spectrum Pharmaceuticals, Inc. (US) II-52

Trubion Pharmaceuticals, Inc. II-53

UCB Pharmaceutical (Belgium) II-53

9. GLOBAL MARKET PERSPECTIVE II-54

Table 4: World Recent Past, Current & Future Analysis for

Anti-CD20 Monoclonal Antibodies Market by Geographic Region -

US and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2006 through

2015 (includes corresponding Graph/Chart) II-54

Table 5: World 10-year Perspective for Anti-CD20 Antibodies

Market by Geographic Region - Percentage Breakdown of Value

Sales for US and Rest of World Markets for Years 2006, 2010 &

2015 II-54

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 38 (including Divisions/Subsidiaries - 44)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 28

Canada 1

Japan 2

Europe 11

France 2

Germany 2

The United Kingdom 1

Rest of Europe 6

Asia-Pacific (Excluding Japan) 2

------------------------------------------

To order this report:Biopharmaceutical Industry: Global Anti-CD20 Monoclonal Antibodies Industry

Biopharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... new market research report "Ablation Technologies Market by Product ... Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global ... the global market over the forecast period of 2015 ... Billion by 2020, at CAGR of 10.5% from 2015 ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
(Date:2/8/2016)...  As part of a major growth and expansion initiative, ... Lori Chmura as President of Dune Inc., its ... Chmura,s extensive experience in the medical device space will play ... --> --> In ... sales, marketing and operational functions in the U.S. She is ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub ... According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating ... balancing and detoxifying the body. , A former motivational speaker, Perry A~ has since ...
(Date:2/8/2016)... ... , ... FileHold's document management software has been implemented by ... environment for FileHold software that is pay per user subscription-based and also does ... FileHold web services API. DocuSyst also advises clients on fully functioning back up ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
(Date:2/8/2016)... NV (PRWEB) , ... February 08, 2016 , ... Guruji ... February 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... true happiness. Mahendra Trivedi is known by over 250,000 people from over 40 ...
Breaking Medicine News(10 mins):